title: The combination ace-inhibitors plus canreonate in patients with anterior myocardial infarction: safety and tolerability study.
abstract: BACKGROUND
  There is recent evidence that aldosterone (ALDO) exerts pro-fibrotic effects, acting via the mineral-corticoid receptors in cardiovascular tissues and partial aldosterone escape during ACE-inhibition treatment occurs.
  
  
  METHODS
  A double blind randomised study was performed to evaluate the feasibility, and tolerability of the administration of the 25 mg/day of canreonate plus captopril versus captopril alone in patients with anterior AMI unsuitable for thrombolysis and/or not receiving thrombolytic treatment, and unreperfused after thrombolysis. Fifty five patients hospitalised for anterior AMI,with a serum creatinine concentration <2.0 mg/dl and a serum K concentration <5.0 mmol per liter were randomised in 2 groups: Group A included 27 patients who received captopril and 25 mg i.v. of canreonate (1 mg/h for the 1st 72 h and then orally 25 mg/day. Group B (28 patients) received captopril and placebo. Ten days after admission they underwent echocardiography to determine end systolic volume (ESV), ejection fraction (EF), End diastolic diameter EDD, E/A ratio, E deceleration time (dec. time) and isovolumetric relaxation time (IVRT), E and A peak velocities.
  
  
  RESULTS
  All patients did not show patency of the infarct related artery (7-10 days after AMI) and the 2 groups were similar in regard to age, sex, diabetes, smoking habits, hypertension, CK enzymatic peak, adjuvant therapy, EF, ESV, and incidence of CABG/PTCA. One patient only showed increase of serum K>5.5 mmol/dl and creatinine >2.0 mg per liter after 10 days of treatment (group A). The mitral E/A ratio was higher in group A than group B (0.85+/-0.18 and 0.75+/-0.14) respectively, P=0.024. Creatinine, blood urea and serum K did not show significant differences between groups. No side effects were observed during the study period. The incidence of vessel diseases was similar in both groups.
  
  
  CONCLUSIONS
  Our data suggest that the combination of captopril plus canreonate in feasible in early treatment of AMI patients.
authors.affiliation: Division of Cardiology, Paolo Borsellino, G.F. Ingrassia Hospital, Palermo, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Di Pasquale
authors.forename: V
authors.initials: V
authors.lastname: Alessi
authors.forename: O
authors.initials: O
authors.lastname: Barberi
authors.forename: A
authors.initials: A
authors.lastname: Scandurra
authors.forename: V
authors.initials: V
authors.lastname: Bucca
authors.forename: G
authors.initials: G
authors.lastname: Maringhini
authors.forename: S
authors.initials: S
authors.lastname: Scalzo
authors.forename: S
authors.initials: S
authors.lastname: Paterna
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002191:Canrenoic Acid / Q000627:therapeutic use*; D002216:Captopril / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002191:Canrenoic Acid; D002216:Captopril